The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Feathers are one of the most recognizable characteristics of modern birds, and a trait that was also shared by several non-avian dinosaurs. Based on the current distribution of fossil evidence, it appears that feathers were an ancestral dinosaurian trait, though one that may have been selectively lost in some species. Direct fossil evidence of feathers or feather-like structures has been discovered in a diverse array of species in many non-avian dinosaur groups, both among saurischians and ornithischians. Simple, branched, feather-like structures are known from heterodontosaurids, primitive neornithischians, and theropods, and primitive ceratopsians. Evidence for true, vaned feathers similar to the flight feathers of modern birds has been found only in the theropod subgroup Maniraptora, which includes oviraptorosaurs, troodontids, dromaeosaurids, and birds. Feather-like structures known as pycnofibres have also been found in pterosaurs. However, researchers do not agree on whether these structures share a common origin between lineages (i.e., they are homologous), or if they were the result of widespread experimentation with skin coverings among ornithodirans. If the former is the case, filaments may have been common in the ornithodiran lineage and evolved before the appearance of dinosaurs themselves. Research into the genetics of American alligators has revealed that crocodylian scutes do possess feather-keratins during embryonic development, but these keratins are not expressed by the animals before hatching.
=== Specific proposals === A variety of government task forces, expert panels, private institutions, politicians, and journalists have made recommendations for reducing the deficit and slowing the growth of debt. Several organizations have compared the future impact of these plans on the deficit, debt, and economy. One helpful way of measuring the impact of the plans is to compare them in terms of revenue and expense as a percentage of GDP over time, in total and by category. This helps illustrate how the different plan authors have prioritized particular elements of the budget.
=== Co–Coo === Philip Cohen FRS (b. 1945). At the University of Dundee known primarily for work on protein phosphorylation and ubiquitinylation. Stanley Cohen (1922–2020). American biochemist at Vanderbilt University. Nobel Prize in Physiology or Medicine (1986). Edwin Joseph Cohn (1892–1953). American protein chemist at Harvard, known for studies on blood and the physical chemistry of protein. Author, with John Edsall of Proteins, Amino Acids and Peptides, a very influential book. Member Natl. Acad. Sci. USA. Mildred Cohn (1913–2009). American biochemist, at the University of Pennsylvania, pioneer in the use of nuclear magnetic resonance to study enzyme reactions. Waldo Cohn (1910–1999). American biochemist at Oak Ridge National Laboratory, known for developing techniques for separating isotopes. Linda Columbus (active from 2002). American chemist at the University of Virginia known for work on membrane proteins. Sidney Colowick (1916–1985). American biochemist at Vanderbilt University and founding editor of Methods in Enzymology. Member Natl. Acad. Sci. USA. Minor J. Coon (1921–2018). American biochemist at the University of Michigan, Ann Arbor, discoverer of 3-hydroxy-3-methylglutaryl-CoA.
Sources: en.wikipedia.org
The hypothalamus uses thyrotropin-releasing hormone (TRH or thyroliberin) to tell the pituitary to release thyrotropin. The hypothalamus uses corticotropin-releasing hormone (CRH or corticoliberin) to tell the pituitary to release corticotropin. The hypothalamus uses gonadotropin-releasing hormone (GnRH or gonadoliberin) to tell the pituitary to release gonadotropin. The hypothalamus uses growth hormone–releasing hormone (GHRH or somatoliberin) to tell the pituitary to release somatotropin. The main release-inhibiting hormones or inhibiting hormones are as follows:
This category includes the Community of Latin American and Caribbean States (CLACS), Council of Europe (CoE), European Union (EU), Eurasian Economic Union (EAEU), Energy Community, North Atlantic Treaty Organization (NATO), Economic Community of West African States (ECOWAS), Organization for Security and Co-operation in Europe (OSCE), African Union (AU), Organization of American States (OAS), Association of Caribbean States (ACS), Association of Southeast Asian Nations (ASEAN), Islamic Development Bank, Union of South American Nations, Asia Cooperation Dialogue (ACD), Pacific Islands Forum, South Asian Association for Regional Cooperation (SAARC), Asian-African Legal Consultative Organization (AALCO) and the Organisation of Eastern Caribbean States (OECS).
=== Abnormal redox metabolism === An imbalance in glutathione-dependent redox metabolism has been shown to be associated with autism spectrum disorder (ASD). Glutathione synthesis and intracellular redox balance are related to folate metabolism and methylation, metabolic pathways that have also been shown to be abnormal in ASD. Together, these metabolic abnormalities define a distinct endophenotype of TSA closely associated with genetic, epigenetic and mitochondrial abnormalities, as well as environmental factors related to ASD. Glutathione is involved in neuroprotection against oxidative stress and neuroinflammation by improving the antioxidant stress system. In autistic children, studies have shown that glutathione metabolism can be improved.
== Background == Chinese Communist Party general secretary Xi Jinping and United States president Donald Trump held their first meeting during Trump's second presidency at the Busan Summit on 30 October 2025. At the meeting, Trump announced plans to visit China in April of the following year and invited Xi to visit the United States at an appropriate time. The state visit was planned for the first week of April, but the meeting was postponed to May due to the 2026 Iran war. On 25 March, The White House announced Trump's visit would last from 12 to 15 May. In the lead-up to the summit, regional security concerns regarding the conflict with Iran became a key diplomatic focus. On 16 April, Defense Secretary Pete Hegseth announced that Beijing had provided high-level assurances to the White House that it would not send weapons to Iran, explicitly ruling out the potential transfer of surface-to-air missiles to the Iranian military. Hegseth attributed this breakthrough to the "strong and direct relationship" between President Trump and Xi Jinping, noting that the assurances were vital for the upcoming meeting in Beijing. U.S. secretary of state Marco Rubio met on 13 February with Wang Yi, director of the Office of the Central Foreign Affairs Commission and foreign minister. The two sides discussed President Donald Trump's planned visit to China. On 30 April, Wang held a phone call with Rubio to conduct preliminary communication regarding subsequent head-of-state diplomacy. Steve Daines led the first bipartisan U.S.
Sources: en.wikipedia.org
==== Portugal ==== Founded in 1970, the SEDES is one of the oldest Portuguese civic associations and think tanks. Contraditório think tank was founded in 2008. Contraditório is a non-profit, independent and non-partisan think tank.
Constanza Vieira (July 16, 2010). "'Let's talk about the disappeared'". Inter Press Service. Archived from the original on July 18, 2010. "Indigenous Community in Colombia Fears Start of "Dirty War". Democracy Now!. Archived from the original on February 23, 2006. Retrieved February 24, 2006. Guests: Ezequiel Vitonas, former mayor of Toribio, and Manuel Rozental, human rights activist. Interviewers: Juan Gonzalez and Amy Goodman. Segment available in and via streaming real audio , 128k streaming Real Video or MP3 download. The Colombian Miracle Archived October 18, 2015, at the Wayback Machine
== Origin and properties == The Natural History by the Roman writer Pliny the Elder includes a few sentences about a volcanic glass called obsidian (lapis obsidianus), discovered in Ethiopia by Obsidius, a Roman explorer. Obsidian is formed from quickly cooled lava. Extrusive formation of obsidian may occur when felsic lava cools rapidly at the edges of a felsic lava flow or volcanic dome, or when lava cools during sudden contact with water or air. Intrusive formation of obsidian may occur when felsic lava cools along the edges of a dike. Tektites were once thought by many to be obsidian produced by lunar volcanic eruptions, though few scientists now adhere to this hypothesis. Obsidian is mineral-like, but not a true mineral because, as a glass, it is not crystalline; in addition, its composition is too variable to be classified as a mineral. It is sometimes classified as a mineraloid. Though obsidian is usually dark in color, similar to mafic rocks such as basalt, the composition of obsidian is extremely felsic. Obsidian consists mainly of SiO2 (silicon dioxide), usually 70% by weight or more; the remainder consists of variable amounts of other oxides, mostly oxides of aluminium, iron, potassium, sodium and calcium. Crystalline rocks with a similar composition include granite and rhyolite. Because obsidian is metastable at the Earth's surface (over time the glass devitrifies, becoming fine-grained mineral crystals), obsidian older than Miocene in age is rare. Exceptionally old obsidians include a Cretaceous welded tuff and a partially devitrified Ordovician perlite.
CDP-4-dehydro-6-deoxy-D-glucose + NAD(P)H + H+ The 4 substrates of this enzyme are CDP-4-dehydro-3,6-dideoxy-D-glucose, nicotinamide adenine dinucleotide ion, nicotinamide adenine dinucleotide phosphate ion, and water, whereas its 4 products are CDP-4-dehydro-6-deoxy-D-glucose, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, and hydrogen ion. This enzyme belongs to the family of oxidoreductases, specifically those acting on CH or CH2 groups with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is CDP-4-dehydro-3,6-dideoxy-D-glucose:NAD(P)+ 3-oxidoreductase. Other names in common use include CDP-4-keto-6-deoxyglucose reductase, cytidine diphospho-4-keto-6-deoxy-D-glucose reductase, cytidine diphosphate 4-keto-6-deoxy-D-glucose-3-dehydrogenase, CDP-4-keto-deoxy-glucose reductase, CDP-4-keto-6-deoxy-D-glucose-3-dehydrogenase system, and NAD(P)H:CDP-4-keto-6-deoxy-D-glucose oxidoreductase. This enzyme participates in starch and sucrose metabolism.
== Role in Human Pathology == SUMO protein is implicated in the etiology of many biomedical disease states not limited to: cancer, atherosclerosis, cardiovascular disease, neurodegenerative disease, diabetes, liver disease, intestinal disorders, and even infectious disease. In the case of the well-studied cancer tumor suppressor known as p53, there is a regulatory ubiquitin ligase protein in humans called Mouse Double Minute 2 protein, or MDM2, which acts to remove p53 from the cell. MDM2 regulates itself through self-ubiquitination by way of a RING finger domain, targeting itself for proteasomal destruction. When it is SUMOylated at the RING finger domain, MDM2 no longer limits its own function in the cell. When protected from itself, it likewise ubiquitinates p53, marking the protective p53 for destruction instead, whose absence is understood to promote cancer. Here again, the base case is SUMOylation, which is actively being undone by newly discovered SUMO protease SUSP4 and also by the SUMO protease interaction of SMT3IP1/SENP3 which is understood to deSUMOylate both MDM2 and p53. One of the ways p53 functions is as a DNA-binding tetramer; interestingly, SUMOylation of p53 delocalizes it from the nucleus, which prevents such activity. The critical nature of p53 cannot be overstated: in fact, if a human carries only one non-functioning copy of p53, it results in a deadly cancer prognosis known as Li-Fraumeni syndrome.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.